Tysabri

Biogen, Inc. (NASDAQ: BIIB) disclosed in its second-quarter earnings report that it recorded $900 million related to a settlement agreement to resolve previously disclosed "qui tam" litigation related to its conduct before 2015. Qui tam is a type of whistleblower...

Perrigo Company PLC (NYSE: PRGO) disclosed a possible $1.9 billion tax liability after Thursday's close, prompting a plunge in share price. The company plans to appeal Irish tax authorities on behalf of its Elan Pharmaceuticals, whose Tysabri intellectual property and Biogen Idec assets were...

Analysts at Stifel turned bullish on Biogen Inc (NASDAQ: BIIB) for four key reasons. The firm's Thomas Shrader upgrades Biogen's stock from Hold to Buy with a price target boosted from $300 to $415. First, there have been no news reports on the "gigantic" aducanumab phase 3 trial, which started in...

Perrigo Company plc Ordinary Shares (NYSE: PRGO) announced on Monday it would divest its rights to the royalty stream from the global net sales of multiple sclerosis drug Tysabri in favor of privately-held Royalty Pharma. Tysabri is a drug used to treat multiple sclerosis, or MS, a...

Following the release of preliminary results for 2016 by Perrigo Company plc Ordinary Shares (NYSE: PRGO), Deutsche Bank offered seven key takeaways from the earnings call. 7 Takeaways The seven takeaways outlined by analysts Gregg Gilbert and Greg Fraser were as follows: Management confidence...

Leerink's Global Healthcare Conference kicked off Wednesday and will continue through Thursday. Here is a summary of what Leerink's analysts are saying about some of the notable companies who presented at on Wednesday. Universal Health Services Universal Health Services, Inc. (NYSE: UHS)'s chief...

Perrigo Company plc Ordinary Shares (NYSE: PRGO) is considering the potential sale of its non-core businesses, including the lucrative royalty stream from MS drug Tysabri and the prescription pharmaceutical segment. Argus’ Jacob Kilstein maintains a Hold rating on the company. Concerns...

Following the departure of CEO Joseph Papa, along with the subsequent 17 percent cut in the 2016 earnings guidance and the associated uncertainty regarding its strategy, Perrigo Company plc Ordinary Shares (NYSE: PRGO) have taken a hit. Argus’ Jacob Kilstein maintains a Hold rating on the...

Barclays said in a research note that it sees 44–48 percent upside in Perrigo Company plc Ordinary Shares (NYSE: PRGO) to $131–$138, given its view that a more focused company could optimize performance of its consumer healthcare and branded healthcare business. The firm sees $1.60...

Activist investor Starboard Value wrote a letter on Monday to Perrigo Company plc Ordinary Shares (NYSE: PRGO), in which it implored the company to take steps to boost shareholder value as its stock is "deeply undervalued." Starboard's words were echoed by Gregg Gilbert, an analyst at Deutsche Bank...

Biogen Inc (NASDAQ: BIIB) has an aging MS franchise, but a solid biosimilar pipeline is sure to offset the loss of Tecfidera, Avonex and Tysabri. Bernstein's Aaron Gal initiated Biogen at outperform and set a price target of $282. The multiple sclerosis franchise has a five-year runway as...

While naming its new CEO, Perrigo Company plc Ordinary Shares (NYSE: PRGO) also lowered its 2016 guidance, within nine weeks of having issued it. Morgan Stanley’s David Risinger maintained an Equal-Weight rating on the company, while lowering the price target from $151 to $112, to reflect...